Tuesday, April 28, 2026

Apple Loses Key Executive: AI Talent War Heats Up Global Politics

Tech giants are competing for AI talent with high salaries while automating existing roles, highlighting a workforce divide.

New Diabetes Treatment: Chong Kun Dang’s Dubiempol Sustained Release Tablet Approved for Type 2 Diabetes in Korea

Chong Kun Dang's type 2 diabetes treatment, Dubiempol, gains approval, offering a new option for patients with uncontrolled blood sugar.

Thrills in Tokyo: Korean Team’s Last-Minute Free Throw Seals Dramatic Win!

The rejuvenated South Korean national basketball team...

Tag: Alteogen

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Alteogen Secures U.S. Patent for Keytruda Subcutaneous Injection: What This Means for ALT-B4 and Future Treatments

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.